Safe Use of Cenobamate in Super Refractory Status Epilepticus: A Case Series-Reference-Cited by-同舟云学术

Safe Use of Cenobamate in Super Refractory Status Epilepticus: A Case Series

Published:2023-02-15 Issue:2 Volume:13 Page:169-172
ISSN:1941-8744
Container-title:The Neurohospitalist
language:en
Short-container-title:The Neurohospitalist

Author:

Carlson Julia M.¹^ORCID,Molyneaux Bradley J.¹,Lee Jong Woo¹

Affiliation:

1. Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA

Abstract

Cenobamate is an effective new adjunctive antiseizure medication (ASM) for treatment resistant focal epilepsy. It has broad spectrum anticonvulsant activity and may be a useful medication for super refractory status epilepticus (SRSE), but has not yet been studied in generalized seizures or an inpatient setting. Here we describe 2 SRSE cases where cenobamate was added safely to other treatments. It was uptitrated slowly to reduce the risk of hypersensitivity reactions which have been observed previously with rapid increasing dosages. Both patients achieved seizure control and liberation from intensive care. They have remained seizure free with continued treatment and have not experienced any side effects attributable to cenobamate. Cenobamate warrants further examination in patients with refractory status epilepticus.

Publisher

SAGE Publications

Subject

Neurology (clinical)

Link

http://journals.sagepub.com/doi/pdf/10.1177/19418744221147083

Reference7 articles.

1. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures

2. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial

3. Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability

4. New-onset refractory status epilepticus (NORSE) and febrile infection–related epilepsy syndrome (FIRES): State of the art and perspectives, 2018.

5. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early considerations about the safety of cenobamate in the treatment of status epilepticus;Neurological Sciences;2024-07-26

2. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System;CNS Drugs;2023-08-21

3. Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature;Medicina;2023-07-28